
Please try another search
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn’s disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Name | Age | Since | Title |
---|---|---|---|
Donald A. Williams | 66 | 2021 | Independent Chairman of the Board |
J. D. Finley | 66 | 2021 | CEO, CFO & Director |
Binxian Wei | 56 | 2019 | Independent Director |
Bruce E. Sands | - | 2024 | Member of Clinical Advisory Board |
Brian Gordon Feagan | - | 2024 | Member of Clinical Advisory Board |
Florian Rieder | - | 2024 | Member of Clinical Advisory Board |
Emil Chuang | 65 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review